CCK
-
Proglumide
Catalog No. A18171 CCK antagonistProglumide is a drug that exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. IProglumide is a known cholecystokinin (CCK) antagonist. Learn More -
Dexloxiglumide
Catalog No. A18541 CCKA receptor antagonistDexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist. Dexloxiglumide, the active enantiomer of Loxiglumide, inhibits smooth muscle cell contractions induced by cholecystokinin-octapeptide (CCK-8). Learn More -
Loxiglumide (CR1505)
Catalog No. A11769 CCK-A receptor antagonistLoxiglumide (CR1505) is a cholecystokinin antagonist Learn More -
Proglumide sodium salt
Catalog No. A13713 CCK antagonistProglumide sodium salt is a non-selective cholecystokinin (CCK) antagonist. It inhibits CCK-stimulated amylase secretion and prevents CCK-induced 2-deoxyglucose uptake in mouse pancreatic acini. Learn More -
Z-360 calcium salt (Nastorazepide calcium salt)
Catalog No. A13671 CCK-2 receptor antagonistZ-360 is a selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity. Learn More -
Nastorazepide (Z-360)
Catalog No. A15984 CCK-2 receptor antagonistNastorazepide is a selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity. Learn More